Tempus AI(NASDAQ) TEM

Tempus helps doctors choose the best treatments for patients by connecting laboratory tests to medical records. It uses artificial intelligence to find patterns in health data for cancer and heart disease. These tools help pharmaceutical companies develop new drugs and match patients to clinical trials.

What Tempus Offers

• Oncology Tests: Next-generation sequencing diagnostics that analyze tumor tissue and blood to identify genetic mutations; these tests include the xT, xE, and xF assays.
• Hereditary Tests: Genetic screening for inherited risks in cancer and rare diseases acquired through the purchase of Ambry Genetics.
• Data Insights: Licensing of de-identified medical records and molecular data to help drug companies with research and development.
• Clinical Trials: Matching services that connect patients to experimental therapies through a network of more than 5,000 healthcare sites.
• Algos: Algorithmic tests that predict cancer origin and identify risks for heart conditions like atrial fibrillation using existing medical data.

A History of Growth

• Launched the TIME Trial program in June 2019 to accelerate patient enrollment in clinical trials using real-time data matching.
• Expanded into heart health by receiving breakthrough status from the FDA for a diagnostic algorithm that detects stroke risk in March 2021.
• Acquired Arterys in October 2022 to add medical imaging analysis and Highline Consulting in January 2022 to provide clinical trial management.
• Purchased Ambry Genetics and OneOme in 2025 to increase testing capabilities in hereditary screening and pharmacogenetics.
• Formed strategic collaborations with AstraZeneca and GSK to support therapeutic programs and data-driven drug discovery.

What Makes the Platform Different

The company operates a vertically integrated platform that combines high-throughput laboratory sequencing with a database of more than 8.6 million de-identified patient records. This network connects to over 55% of oncologists in the United States, allowing for near real-time data exchange between physicians and researchers.

Key Financial Facts

• Revenue reached $367.2 million in Q4 2025, an 83% increase from $200.7 million in Q4 2024.
• Gross profit grew to $329.5 million in Q4 2025, up 170% from the $122.1 million reported in Q4 2024.
• Net loss widened to $54.2 million in Q4 2025 compared to a loss of $13 million in Q4 2024.
• Operating cash flow was negative $218.1 million in Q4 2025, down from negative $39.3 million in Q4 2024.
• The company reported a contract backlog with a remaining total value of over $1.1 billion as of December 31, 2025.

The Final Word

Tempus has transitioned from a specialized cancer testing lab into a broad healthcare data and artificial intelligence provider. Its growth is driven by the integration of clinical records with molecular testing to personalize patient care at scale.